NASDAQ · Financial Statements

Aimei Health Technology Co., Ltd - Ordinary Share (AFJK) Financial Statements

$12.06 NASDAQ: AFJK Market Cap $38.19M

Aimei Health Technology Co., Ltd - Ordinary Share most recently reported annual revenue of $0, net profit of $1.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Aimei Health Technology Co., Ltd - Ordinary Share: net profit was positive in 2 of 3 reported years; the most recent year shows net profit of $1.0M.

Income Statement — 3 Years (USD millions)

Metric202320242025
Revenue$0$0$0
Operating Expenses$0$1.0M$1.0M
Operating Profit$0$-1.0M$-1.0M
Operating Margin0.0%0.0%0.0%
Other Income$0$4.0M$2.0M
Interest$0$0$0
Depreciation$0$0$0
Profit Before Tax$0$3.0M$1.0M
Tax$0$0$0
Net Profit$0$3.0M$1.0M
EPS$0.02$0.28$0.17
Dividend Payout0.0%0.0%0.0%

Quarterly Results — Last 11 Quarters (USD millions)

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$0$0$0$0$0$0$0$0$0$0$0
Operating Expenses$0$0$0$0$0$0$0$0$0$0$0
Operating Profit$0$0$0$0$0$0$0$0$0$0$0
Operating Margin0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Interest$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$0$1.0M$1.0M$1.0M$0$0$0$0$0$0$0
Tax$0$0$0$0$0$0$0$0$0$0$0
Net Profit$0$1.0M$1.0M$1.0M$0$0$0$0$0$0$0
EPS$0.02$0.08$0.07$0.08$0.05$0.02$0.07$0.06$0.02$0.01$-0.03

Over the 3 years reported for Aimei Health Technology Co., Ltd - Ordinary Share, cash stood at $0 in the latest year, shareholders' equity was $12.0M, current assets covered current liabilities 0.00 times.

Balance Sheet — 3 Years (USD millions)

Metric202320242025
Total Assets$70.0M$74.0M$12.0M
Current Assets$1.0M$0$0
Cash$1.0M$0$0
Inventory$0$0$0
Receivables$0$0$0
Fixed Assets$0$0$0
Capital Work in Progress$0$0$0
Investments$70.0M$74.0M$12.0M
Other Assets$0$0$0
Total Liabilities$1.0M$2.0M$4.0M
Current Liabilities$0$1.0M$3.0M
Borrowings$0$0$2.0M
Other Liabilities$1.0M$1.0M$2.0M
Equity$70.0M$74.0M$12.0M
Reserves$70.0M$72.0M$8.0M

For Aimei Health Technology Co., Ltd - Ordinary Share, operating cash flow was positive in 0 of 3 reported years; free cash flow in the latest year was negative at $1.0M; free cash flow was positive in 0 of 3 years; financing activities used $65.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 3 Years (USD millions)

Metric202320242025
Operating Cash Flow$0$-1.0M$-1.0M
Investing Cash Flow$-70.0M$0$64.0M
Financing Cash Flow$0$0$-65.0M
Net Cash Flow$1.0M$-1.0M$0
Free Cash Flow$0$-1.0M$-1.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-2.57
EV / EBITDA-63.83
FCF Yield-0.97%
Quick Ratio0.01
Interest Coverage—
Return 1Y3.05%
Return 3Y—
Return 5Y—

Aimei Health Technology Co., Ltd - Ordinary Share (AFJK) financials — frequently asked questions

What is Aimei Health Technology Co., Ltd - Ordinary Share's annual revenue?

Aimei Health Technology Co., Ltd - Ordinary Share (AFJK) reported annual revenue of $0 in its most recent fiscal year.

What is Aimei Health Technology Co., Ltd - Ordinary Share's net profit?

Aimei Health Technology Co., Ltd - Ordinary Share (AFJK) reported net profit of $1.0M in its most recent fiscal year.

What is AFJK EV/EBITDA?

Aimei Health Technology Co., Ltd - Ordinary Share's enterprise value to EBITDA (EV/EBITDA) ratio is -63.83. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Financial Services StocksLow P/E Financial Services StocksHigh Net Margin Financial Services StocksDividend Financial Services StocksLow Debt Financial Services StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
AFJK Overview AFJK Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.